Leptomeningeal Carcinomatosis Terminated Phase 2 Trials for Erlotinib (DB00530)

IndicationStatusPhase
DBCOND0038074 (Leptomeningeal Carcinomatosis)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00830245A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung CancerTreatment